Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea

Gastroenterology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, 02215,USA.
Gastroenterology (Impact Factor: 13.93). 03/2005; 128(3):764-70. DOI: 10.1053/j.gastro.2004.11.004
Source: PubMed

ABSTRACT Recurrent C difficile -associated diarrhea (CDAD) is associated with a lack of protective immunity to C difficile toxins. A parenteral C difficile vaccine containing toxoid A and toxoid B was reported previously to be safe and immunogenic in healthy volunteers. Our aim was to examine whether the vaccine is also well tolerated and immunogenic in patients with recurrent CDAD.
Subjects received 4, 50-microg intramuscular inoculations of the C difficile vaccine over an 8-week period. Serum antitoxin antibodies were measured by ELISA, and toxin neutralizing activity was evaluated using the tissue culture cytotoxin assay.
Three patients with multiple episodes of recurrent CDAD were vaccinated. Two of the 3 showed an increase in serum IgG antitoxin A antibodies (3-fold and 4-fold increases, respectively) and in serum IgG antitoxin B antibodies (52-fold and 20-fold, respectively). Both also developed cytotoxin neutralizing activity against toxin A and toxin B. Prior to vaccination, the subjects had required nearly continuous treatment with oral vancomycin for 7, 9, and 22 months, respectively, to treat recurrent episodes of CDAD. After vaccination, all 3 subjects discontinued treatment with oral vancomycin without any further recurrence.
A C difficile toxoid vaccine induced immune responses to toxins A and B in patients with CDAD and was associated with resolution of recurrent diarrhea. The results of this study support the feasibility of active vaccination against C difficile and its toxins in high-risk individuals but must be validated in larger, randomized, controlled trials.

Download full-text


Available from: Michael Warny, Aug 18, 2015
  • Source
    • "Furthermore, reduction in recurrence of CDAD was achieved in a Phase I clinical trial with A and B toxin monoclonal antibodies in combination with standard antibiotic therapy (Lowy et al., 2010). In addition, in a small study with three patients with chronic relapsing CDAD, an investigational vaccine using formalininactivated A and B toxoid antigens prevented CDAD recurrence (Sougioultzis et al., 2005). Collectively, these observations provide validation for, and encourage further development of C. difficile toxin A-and B-based vaccines to prevent CDAD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The Clostridium difficile toxins A and B are primarily responsible for symptoms of C. difficile associated disease and are prime targets for vaccine development. We describe a plasmid-based system for the production of genetically modified toxins in a non-sporulating strain of C. difficile that lacks the toxin genes tcdA and tcdB. TcdA and TcdB mutations targeting established glucosyltransferase cytotoxicity determinants were introduced into recombinant plasmids and episomally expressed toxin mutants purified from C. difficile transformants. TcdA and TcdB mutants lacking glucosyltransferase and autoproteolytic processing activities were ~10,000-fold less toxic to cultured human IMR-90 cells than corresponding recombinant or native toxins. However, both mutants retained residual cytotoxicity that could be prevented by preincubating the antigens with specific antibodies or by formalin treatment. Such non-toxic formalin-treated mutant antigens were immunogenic and protective in a hamster model of infection. The remaining toxicity of untreated TcdA and TcdB mutant antigens was associated with cellular swelling, a phenotype consistent with pore-induced membrane leakage. TcdB substitution mutations previously shown to block vesicular pore formation and toxin translocation substantially reduced residual toxicity. We discuss the implications of these results for the development of a C. difficile toxoid vaccine.
    Microbiology 04/2013; 159(Pt 7). DOI:10.1099/mic.0.066712-0 · 2.84 Impact Factor
  • Source
    • "Vaccines containing formaldehyde-inactivated TcdA and TcdB have been developed. In healthy volunteers, this vaccine induced high levels of specific neutralizing immunoglobulin G (IgG) and some promising initial experience has been gained in a few patients with recurrent CDI (Sougioultzis et al., 2005). Although the role of antitoxin immunity in protection from CDI is clear, vaccines based on toxins are unlikely to prevent colonization, and carriage and transmission of C. difficile will therefore remain a persistent threat. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clostridium difficile is a pathogen responsible for diarrhoea and colitis, particularly after antibiotic treatment. We evaluated the C. difficile protease Cwp84, found to be associated with the S-layer proteins, as a vaccine antigen to limit the C. difficile intestinal colonization and therefore the development of the infection in a clindamycin-treated hamster model. First, we evaluated the immune response and the animal protection against death induced by several immunization routes: rectal, intragastric and subcutaneous. Antibody production was variable according to the immunization routes. In addition, serum Cwp84 antibody titres did not always correlate with animal protection after challenge with a toxigenic C. difficile strain. The best survival rate was observed with the rectal route of immunization. Then, in a second assay, we selected this immunization route to perform a larger immunization assay including a Cwp84 immunized group and a control group. Clostridium difficile intestinal colonization and survival rate, as well as the immune response were examined. Clostridium difficile hamster challenge resulted in a 26% weaker and slower C. difficile intestinal colonization in the immunized group. Furthermore, hamster survival in the Cwp84 immunized group was 33% greater than that of the control group, with a significant statistical difference.
    FEMS Immunology & Medical Microbiology 06/2011; 63(1):73-81. DOI:10.1111/j.1574-695X.2011.00832.x · 2.55 Impact Factor
  • Source
    • "Intravenous immune globulin (Leung et al., 1991, Wilcox, 2004) monoclonal antibody therapy (Lowy et al., 2010) and therapeutic vaccines have (Sougioultzis et al., 2005) also been considered, because circulating antibodies to C. difficile toxins are associated with protection from severe CDI in hospital (Kotloff et al., 2001, Aboudola et al., 2003, Kyne et al., 2000, Kyne et al., 2001). None of these agents are approved by the FDA to treat CDI, however, and cannot now be considered for first-line therapy (Balagopal & Sears, 2007, Abougergi et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Clostridium difficile is a well recognized pathogen of humans and animals. Although C. difficile was first identified over 70 years ago, much remains unknown in regards to the primary source of human acquisition and its pathobiology. These deficits in our knowledge have been intensified by dramatic increases in both the frequency and severity of disease in humans over the last decade. The changes in C. difficile epidemiology might be due to the emergence of a hypervirulent stain of C. difficile, ageing of the population, altered risk of developing infection with newer medications, and/or increased exposure to C. difficile outside of hospitals. In recent years, there have been numerous reports documenting C. difficile contamination of various foods, and reports of similarities between strains that infect animals and strains that infect humans as well. The purposes of this review are to highlight the many challenges to diagnosing, treating, and preventing C. difficile infection in humans, and to stress that collaboration between human and veterinary researchers is needed to control this pathogen.
    Zoonoses and Public Health 02/2011; 58(1):4-20. DOI:10.1111/j.1863-2378.2010.01352.x · 2.07 Impact Factor
Show more